血液・腫瘍性疾患患児における抗真菌薬ミカファンギンの有効性に関する検討

書誌事項

タイトル別名
  • Efficacy of Micafungin (MCFG) for Pediatric Patients of Hematological Disorder and Malignant Tumor

この論文をさがす

抄録

We performed a multicenter study to evaluate the efficacy and safety of micafungin (MCFG) in empiric and prophylactic treatment for pediatric patients with neutropenia due to hematopoietic stem cell transplantation or chemotherapy for hematological disorders and malignant tumors. In the prophylactic treatment group, all 17 patients, administered MCFG at a dose of 3.1 mg/kg (range 2.5 to 4.5 mg/kg), showed prophylactic efficacy against fungalinfection. In the empiric treatment group, 14 (70%) of 20 patients, administered MCFG at a dose of 3.8 mg/kg (range 2.6 to 6.0 mg/kg), showed improvements in infectious symptoms. None of the patients required discontinuation, although toxicity developed in 8 (19%) patients, including diarrhea and abdominal pain. This multicenter study demonstrated the effectiveness and safety of MCFG in an empiric and prophylactic treatment for pediatric patients.

収録刊行物

被引用文献 (1)*注記

もっと見る

参考文献 (19)*注記

もっと見る

関連プロジェクト

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ